News

Article

More companies announce ARVO 2025 presentations

Author(s):

Key Takeaways

  • Astellas Pharma will present data on geographic atrophy, focusing on biomarkers, patient experience, and insights from the GATHER Phase 3 studies of IZERVAY.
  • Kodiak Sciences will highlight its ABC platform's versatility in developing treatments for complex ocular diseases, with a focus on ocular inflammatory disease and geographic atrophy.
SHOW MORE

Discover groundbreaking research and presentations from leading companies at the ARVO 2025 Annual Meeting, advancing ophthalmology and patient care.

Image credit: AdobeStock/Art_me2541

(Image credit: AdobeStock/Art_me2541)

As we near the final days before one of the biggest meetings in ophthalmology, more companies are announcing the presentation of their data at the event. The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, is being held from May 4-8 in Salt Lake City, Utah.

Ophthalmology Times will be onsite to cover the key data at this event. Be sure to stay tuned to our coverage for interviews with primary investigators and researchers who will be giving podium presentations at the event. Don’t forget to check our previously published list of companies with scheduled presentations.

Note: The following list of presentations are in alphabetical order by company. Updates may be added to this article as new information becomes available.

Astellas Pharma Inc.

The company is scheduled to highlight new data that enhances continued understanding of the science of geographic atrophy (GA), and the experience of patients living with the progressive disease at the 2025 ARVO Annual Meeting. The data comprises 9 abstracts, including 2 oral presentations, featuring analyses on biomarkers, patient experience, mechanism of disease and other insights from the GATHER Phase 3 studies of IZERVAY for the treatment of GA secondary to age-related macular degeneration (AMD).1

Kodiak Sciences

Kodiak will have 7 scientific presentations on its research programs at the ARVO 2025 annual meeting, which will highlight the power and versatility of Kodiak's ABC (Antibody Biopolymer Conjugate) platform for the design and development of new medicines for complex multifactorial diseases with a high unmet need. The presentations will center on the company’s research on ocular inflammatory disease and GA.2

MERIT

MERIT will present a poster at ARVO 2025 highlighting a potentially groundbreaking morphological endpoint. The poster, titled “Outer Retina-Choroid en face Image, ORC™: Characterization of A Novel Morphologic Endpoint for Dry Age-Related Macular Degeneration,” will be presented on May 8, 2025. The company states that ORC represents a potential step forward for clinical endpoints in dry AMD, and specifically its late-stage form of GA. While GA lesion size is generally measured using Fundus Autofluorescence (FAF), ORC offers a new method derived from optical coherence tomography (OCT) B-scans assisted by deep learning tools that is agnostic to the imaging device manufacturer.3

Reference:
  1. Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses. Astellas Pharma Inc. May 1, 2025. Accessed May 2, 2025. https://www.biospace.com/press-releases/astellas-to-present-new-data-in-geographic-atrophy-at-upcoming-ophthalmology-annual-congresses
  2. Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases. Kodiak Sciences. May 1, 2025. Accessed May 2, 2025. https://www.streetinsider.com/PRNewswire/Kodiak+Sciences+Data+at+ARVO+2025+Highlight+Power+and+Versatility+of+ABC+Platform+in+Addressing+Complex+Multifactorial+Ocular+Diseases/24730377.html
  3. MERIT to Showcase Novel Morphological Endpoint at ARVO 2025 Poster Presentation. MERIT. May 1, 2025. Accessed May 2, 2025. https://www.westernslopenow.com/business/press-releases/ein-presswire/807759977/merit-to-showcase-novel-morphological-endpoint-at-arvo-2025-poster-presentation/

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.